Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be undergoing their first cardiac allograft transplant~* Women of childbearing potential must have a negative serum pregnancy test within 48 hours prior to transplantation~* Women of childbearing potential must use two reliable forms of contraception simultaneously. Effective contraception must be used before beginning study drug therapy, and for 4 months following discontinuation of study drug therapy~* Participants and/or their guardians must be willing and be capable of understanding risks and comply with the purpose of the study~Exclusion Criteria:~* Previous organ transplants~* Participants receiving multiple organs~* Participants requiring ventricular assist device (VAD) upon completion of transplantation surgery~* Women lactating, pregnant or of childbearing potential not using, or who are unwilling to use two reliable forms of contraception simultaneously during the study~* History of a psychological illness or condition which would interfere with the participant's ability to understand the requirements of the study~* White blood count =\<2500/mm\^3, platelets =\<50,000/mm\^3 or hemoglobin =\<6 g/dL~* HIV-1, the presence of positive HBsAg, or chronic active hepatitis C~* Active peptic ulcer disease~* Severe diarrhea or other gastrointestinal disorders which might interfere with their ability to absorb oral medication~* Malignancies within the past 5 years, excluding skin carcinoma that have been adequately treated~* Participants who have received within the past 30 days or require concomitant treatment with other investigational drugs or immunosuppressive medications that are prohibited for this study~* Inability to start microemulsion form of cyclosporine within 72 hours

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daclizumab (Type: EXPERIMENTAL): Daclizumab will be administered as a intravenous dose of 1 milligrams per kilogram \[mg/kg\] on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily \[BID\], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg, and 500-1000 mg IV methylprednisolone peri operative switch to oral at 0.5-1 mg/kg/day followed by tapering.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo will be administered on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily \[BID\], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg orally, and 500-1000 mg IV methylprednisolone peri-op switch to oral at 0.5-1 mg/kg/day followed by tapering.

Based on this trial design, predict the completion outcome and termination type (if applicable).